Lewis H Bender insider trades: Interleukin Genetics (ILI) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Lewis reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 24, 2008 | ILI | ↑ Buy | 30,000 | $0.26 | $8K | Direct | Nov 24, 2008 (0d) |
| Nov 20, 2008 | ILI | ↑ Buy | 30,000 | $0.41 | $12K | Direct | Nov 20, 2008 (0d) |
| Feb 19, 2008 | ILI | ↑ Buy | 3,000 | $1.40 | $4K | Direct | Feb 20, 2008 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Lewis H Bender's insider trades
Lewis H Bender is Chief Executive Office at Interleukin Genetics (ILI). Since Feb 19, 2008, Lewis has reported 3 open-market purchases worth $24K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (10 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ILI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.